Purchase U-47700
Discount program, second order - 5%OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy U-47700 for sale
U-47700 is a structural isomer of the earlier opioid AH-7921 and the result of a great deal of work elucidating the scaffold's quantitative structure–activity relationship. Upjohn looked for the key moieties which gave the greatest activity and posted over a dozen patents on related compounds, each optimizing one moiety until they discovered that U-47700 was the most active.
U-47700 is a research opioid compound developed in the 1970s by Upjohn Laboratories. U-47700 has around 7.5 times the potency of morphine in animal models and is currently used in scientific research.
U-47700 is an opioid analgesic drug developed by a team at Upjohn in the 1970s, which has around 7.5 times the potency of morphine in animal models. U-47700 was never marketed; however, since the patent was never renewed, it has been sold on the gray market as a research chemical and recently became available as a new drug in substance mixtures known as 'gray death.'
U-47700 is a chemical substance with opioid agonist properties used in research into new painkillers.
U-47700, also known as despropionyl-U-47700, is a drug that functions as an opioid analgesic. It is derived from Thiofentanyl and Phenylpiperidine. This makes it structurally similar to other fentanyl analogs such as Acetylfentanyl and 4-Fluorofentanyl.
U-47700 is a synthetic opioid that is 7.5 times more potent than morphine, with a potency comparable to that of other semi-synthetic opioids such as DADLE, which has led some to call it super heroin.
U-47700 is one of the most potent opioid analgesics. In laboratories, it is used as a pharmacological tool to study the analgesic effects of other opioids and to characterize their unwanted side effects and potency.
U-47700, also known as 4-Cyano-4-(methyl nitro methyl)piperidine, is a synthetic opioid analgesic that is selective for µ-opioid receptors.
U-47700 is an opioid used for research purposes.
U-47700 is a research chemical belonging to the opioid class of drugs.
U-47700 is a structural analog of the synthetic opioids AH-7921 and XLR11.
It's an extremely potent synthetic opioid drug, over 100 times stronger than morphine.
U-47700 is a synthetic opioid ligand with high binding affinity and selectivity for the κ-opioid receptor. As such, it has a powerful analgesic effect in experimental models but has been associated with significant respiratory depression.
U-47700, also known as U4, pink heroin, pinky, and pink, is an opioid analgesic drug developed by a team at Upjohn in the 1970s, which has around 7.5 times the potency of morphine in animal models. U-47700 is a structural isomer of the earlier opioid AH-7921 and the result of a great deal of work elucidating the scaffold's quantitative structure–activity relationship.
U-47700, also known as N-(1-[2-(dimethylamino)cyclohexyl]-1H-indol-3-yl)-N-phenylpropanolamine, is a synthetic opioid analgesic drug and analog of U-47700 developed by a team at Upjohn in the 1970s which has around 7.5 times the potency of morphine in animal models.
U-47700 (7--hydroxy-N-[1-(2-phenylmethyl)-4-piperidinyl]-6,14-endoethenomorphone) is a synthetic opioid analgesic of the benzomorphan family developed by Upjohn in the 1970s and 1980s. It is a potent agonist of all four major classes of opioid receptors (delta, kappa, mu and nociceptin) but only roughly 1/20th as potent as morphine.
U-47700 is a new uncontrolled synthetic psychoactive drug identified in the European Union and is currently not approved for medical or psychiatric use in the United States. This research report addresses the health risk of U-47700 and its synthetic analogs in the illicit drug market, as well as recent drug regulatory activity worldwide.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
200g $690
100mg $840
100mg $840
100g $500
1kg $1890
100g $490
200g $690
200g $690
500g $1080
100g $390
-min-200x127.JPG)
1kg $1690
100g $490